Vorapaxar sulfate (BioDeep_00000701890)
代谢物信息卡片
Vorapaxar sulfate
化学式: C29H35FN2O8S (590.2098042)
中文名称: 沃拉帕沙
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C.OS(=O)(=O)O
InChI: /m1./s1
描述信息
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
C78274 - Agent Affecting Cardiovascular System
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:83314
- KEGGdrug: D09766
- PubChem: 10077129
- ChEMBL: CHEMBL2107386
- CAS: 705260-08-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Mohammed A Abosheasha, Afnan H El-Gowily, Abdo A Elfiky. Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
Journal of thrombosis and thrombolysis.
2022 Feb; 53(2):273-281. doi:
10.1007/s11239-021-02558-5. [PMID: 34510337] - Zhuang-Zhuang Tang, Pan-Pan Gu, Xiao-Fei An, Ling-Shan Gou, Yao-Wu Liu. Lack of miRNA-17 family mediates high glucose-induced PAR-1 upregulation in glomerular mesangial cells.
Naunyn-Schmiedeberg's archives of pharmacology.
2022 01; 395(1):77-85. doi:
10.1007/s00210-021-02184-1. [PMID: 34792626] - Julian Friebel, Eileen Moritz, Marco Witkowski, Kai Jakobs, Elisabeth Strässler, Andrea Dörner, Daniel Steffens, Marianna Puccini, Stella Lammel, Rainer Glauben, Franziska Nowak, Nicolle Kränkel, Arash Haghikia, Verena Moos, Heinz-Peter Schutheiss, Stephan B Felix, Ulf Landmesser, Bernhard H Rauch, Ursula Rauch. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Cells.
2021 12; 10(12):. doi:
10.3390/cells10123517. [PMID: 34944024] - Ian C Gilchrist, David A Morrow, Mark A Creager, Jeffrey W Olin, Benjamin M Scirica, Erica L Goodrich, Marc P Bonaca. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial.
Journal of the American Heart Association.
2021 10; 10(20):e021412. doi:
10.1161/jaha.121.021412. [PMID: 34622665] - Sarah W Y Lok, Wai Han Yiu, Hongyu Li, Rui Xue, Yixin Zou, Bin Li, Kam Wa Chan, Loretta Y Y Chan, Joseph C K Leung, Kar Neng Lai, Sydney C W Tang. The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis.
Clinical science (London, England : 1979).
2020 11; 134(21):2873-2891. doi:
10.1042/cs20200923. [PMID: 33078834] - Krishna Sriram, Paul A Insel. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?.
British journal of pharmacology.
2020 11; 177(21):4971-4974. doi:
10.1111/bph.15194. [PMID: 32639031] - Christoph B Olivier, Vandana Sundaram, Glenn M Chertow, Sumana Shashidhar, Lori K McDonnell, Victoria Y Ding, Manisha Desai, Kenneth W Mahaffey, Matthew Mell. A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.
The journal of vascular access.
2020 Jul; 21(4):467-474. doi:
10.1177/1129729819887269. [PMID: 31774037] - Daisuke Noguchi, Naohisa Kuriyama, Takahiro Ito, Takehiro Fujii, Hiroyuki Kato, Shugo Mizuno, Hiroyuki Sakurai, Shuji Isaji. Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
The Journal of surgical research.
2020 02; 246(?):568-583. doi:
10.1016/j.jss.2019.09.044. [PMID: 31653415] - Maaike Waasdorp, Sandrine Florquin, JanWillem Duitman, C Arnold Spek. Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2019 10; 33(10):10966-10972. doi:
10.1096/fj.201900516r. [PMID: 31287960] - Jianliang Pang, Peiyang Hu, Junwei Wang, Jinsong Jiang, Jifu Lai. Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF‑κB signaling pathways.
Molecular medicine reports.
2019 Jun; 19(6):5291-5300. doi:
10.3892/mmr.2019.10211. [PMID: 31059055] - Simon Correa, Marc P Bonaca, Benjamin M Scirica, Sabina A Murphy, Erica L Goodrich, David A Morrow, Michelle L O'Donoghue. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
Journal of thrombosis and thrombolysis.
2019 Apr; 47(3):353-360. doi:
10.1007/s11239-018-1779-y. [PMID: 30511258] - Michael P Bokoch, Hyunil Jo, James R Valcourt, Yoga Srinivasan, Albert C Pan, Sara Capponi, Michael Grabe, Ron O Dror, David E Shaw, William F DeGrado, Shaun R Coughlin. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
Biochemistry.
2018 10; 57(39):5748-5758. doi:
10.1021/acs.biochem.8b00577. [PMID: 30102523] - Bart L van den Eshof, Arie J Hoogendijk, Pelle J Simpson, Floris P J van Alphen, Sara Zanivan, Koen Mertens, Alexander B Meijer, Maartje van den Biggelaar. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics.
Arteriosclerosis, thrombosis, and vascular biology.
2017 10; 37(10):1891-1902. doi:
10.1161/atvbaha.117.309926. [PMID: 28818855] - W K Kraft, J H Gilmartin, D L Chappell, F Gheyas, B M Walker, S Nagalla, U P Naik, J C Horrow, R E Wrishko, S Zhang, M S Anderson. Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects.
Clinical and translational science.
2016 08; 9(4):221-7. doi:
10.1111/cts.12405. [PMID: 27304196] - Peter Ellinghaus, Elisabeth Perzborn, Peter Hauenschild, Christoph Gerdes, Stefan Heitmeier, Mayken Visser, Holger Summer, Volker Laux. Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran.
Thrombosis research.
2016 Jun; 142(?):44-51. doi:
10.1016/j.thromres.2016.04.008. [PMID: 27131284] - Vinay Bhal, Michael J Herr, Mason Dixon, Steve Akins, Ed Hord, Melanie M White, Dietmar Seiffert, Jayaprakash Kotha, Lisa K Jennings. Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
Thrombosis research.
2015 Dec; 136(6):1216-23. doi:
10.1016/j.thromres.2015.09.009. [PMID: 26412559] - Victor L Serebruany, Ales Tomek, Alex N Pokov, Moo Hyun Kim. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?.
Expert review of cardiovascular therapy.
2015 Dec; 13(12):1333-44. doi:
10.1586/14779072.2015.1101343. [PMID: 26513059] - Sally A Arif, Jennifer D'Souza, Monika Gil, Suzanna Gim. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2015 Oct; 72(19):1615-22. doi:
10.2146/ajhp140758. [PMID: 26386102] - Brian E Hawes, Ying Zhai, David Hesk, Mark Wirth, Huijun Wei, Madhu Chintala, Dietmar Seiffert. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
European journal of pharmacology.
2015 Sep; 762(?):221-8. doi:
10.1016/j.ejphar.2015.05.046. [PMID: 26022529] - Tian-Quan Cai, L Alexandra Wickham, Gary Sitko, Maria Strainer Michener, Richard Raubertas, Larry Handt, Madhu Chintala, Dietmar Seiffert, Michael Forrest. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
European journal of pharmacology.
2015 Jul; 758(?):107-14. doi:
10.1016/j.ejphar.2015.03.073. [PMID: 25857224] - Heather M Judge, Lisa K Jennings, David J Moliterno, Edward Hord, Rosemary Ecob, Pierluigi Tricoci, Tyrus Rorick, Jayaprakash Kotha, Robert F Storey. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Platelets.
2015; 26(3):236-42. doi:
10.3109/09537104.2014.902924. [PMID: 24750101] - Michael J V White, Elkin Galvis-Carvajal, Richard H Gomer. A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p.
Journal of immunology (Baltimore, Md. : 1950).
2015 Jan; 194(1):142-50. doi:
10.4049/jimmunol.1401777. [PMID: 25429068] - Jeff Sigler. Drug updates and approvals: 2014 in review.
The Nurse practitioner.
2014 Dec; 39(12):14-23; quiz 23. doi:
10.1097/01.npr.0000456393.83499.90. [PMID: 25350291] - Robert F Storey, Jayaprakash Kotha, Susan S Smyth, David J Moliterno, Tyrus L Rorick, Tiziano Moccetti, Marco Valgimigli, Jean Pierre Dery, Jan H Cornel, Gregory S Thomas, Kurt Huber, Robert A Harrington, Edward Hord, Heather M Judge, Edmond Chen, John Strony, Kenneth W Mahaffey, Pierluigi Tricoci, Richard C Becker, Lisa K Jennings. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Thrombosis and haemostasis.
2014 May; 111(5):883-91. doi:
10.1160/th13-07-0624. [PMID: 24402559] - Paul Statkevich, Teddy Kosoglou, Richard A Preston, Bharath Kumar, Fengjuan Xuan, Craig Trusley, James E Schiller, Ronald B Langdon, David L Cutler. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.
European journal of clinical pharmacology.
2012 Nov; 68(11):1501-8. doi:
10.1007/s00228-012-1269-7. [PMID: 22527342] - Teddy Kosoglou, Walter K Kraft, Bharath Kumar, Paul Statkevich, Fengjuan Xuan, Lei Ma, Lisa K Jennings, James E Schiller, Ronald B Langdon, David L Cutler. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.
European journal of clinical pharmacology.
2012 Jul; 68(7):1049-56. doi:
10.1007/s00228-012-1217-6. [PMID: 22315147] - Cristina I Tama, Jim X Shen, James E Schiller, Roger N Hayes, Robert P Clement. Determination of a novel thrombin receptor antagonist (SCH 530348) in human plasma: evaluation of Ultra Performance Liquid Chromatography™-tandem mass spectrometry for routine bioanalytical analysis.
Journal of pharmaceutical and biomedical analysis.
2011 May; 55(2):349-59. doi:
10.1016/j.jpba.2011.01.045. [PMID: 21353434]